Management of Acute Deep Vein Thrombosis

Introduction to Treatment

• Acute deep vein thrombosis (DVT) treatment can be managed at home for patients with adequate home circumstances, as recommended by the American College of Chest Physicians 1, 2
• Anticoagulation therapy is recommended for patients with DVT to prevent recurrence and pulmonary embolism, with a minimum treatment of 3 months, and consideration of extended therapy for those with low to moderate bleeding risk, as recommended by the ACCP and the International Society on Thrombosis and Haemostasis (ISTH) 3, 4, 5

Anticoagulation Options

• Direct oral anticoagulants (DOACs) like rivaroxaban are recommended at a dose of 15 mg twice daily for 21 days, then 20 mg once daily, according to the Mayo Clinic Proceedings 6
• Low molecular weight heparin (LMWH) like enoxaparin can be administered at a dose of 1.5 mg/kg once daily or 1 mg/kg twice daily, as stated in the Mayo Clinic Proceedings 6
• Fondaparinux has a weight-based dosing regimen: <50 kg: 5 mg once daily, 50-100 kg: 7.5 mg once daily, and >100 kg: 10 mg once daily, with a contraindication if CrCl <30 mL/min, as reported in the Mayo Clinic Proceedings 6
• Warfarin should be initiated at a typical dose of 5 mg once daily, with a target INR of 2.0-3.0 (goal 2.5), and must overlap with parenteral anticoagulation for a minimum of 5 days and until INR ≥2.0 for at least 24 hours, as recommended in the Mayo Clinic Proceedings and the American College of Chest Physicians 1, 6
• Vitamin K antagonists (VKAs) like warfarin are an alternative, with a target INR range of 2.0-3.0 (target 2.5), as recommended by the ACCP 1

Dosing and Administration

• The initial and maintenance doses of unfractionated heparin (UFH) are as follows:

• DOACs are renally cleared and may require dose adjustment or avoidance in patients with severe renal impairment, and missed doses can increase the risk of thromboembolism due to their short half-lives 8

Special Considerations

• Low molecular weight heparin (LMWH) is preferred over VKAs for patients with cancer-associated thrombosis, as recommended by the ACCP 1
• Adjusted-dose VKA (target INR 2.5) is recommended for antiphospholipid syndrome, rather than DOACs, as stated by the ACCP and the European Society of Cardiology (ESC) 9
• The American Society of Hematology supports the immediate transition from heparin to direct oral anticoagulants (DOACs) like apixaban, which has a rapid onset of action (1-3 hours to reach peak plasma concentration) and does not require bridging therapy, due to unfractionated heparin's short half-life (approximately 60-90 minutes) 10

Monitoring and Follow-up

• Clinical monitoring is recommended during and after treatment, with periodic reassessment (e.g., annually) of bleeding risk and continued need for anticoagulation for patients on extended therapy 5, 11
• The European Society of Cardiology recommends scheduling follow-up in 3-6 months with clinical assessment, evaluation of anticoagulation compliance, and consideration of follow-up imaging to assess for progression 12
• Annual reassessment of continued need for anticoagulation, bleeding risk, and medication tolerance and adherence is recommended by the European Society of Cardiology 12

Complications and Risks

• Untreated popliteal vein thrombosis can lead to pulmonary embolism, post-thrombotic syndrome, chronic venous insufficiency, and venous gangrene in severe cases, according to the American College of Radiology (ACR) 13
• Untreated DVT can lead to pulmonary embolism in 50-60% of patients, with an associated mortality rate of 25-30%, according to the ACR 14
• Recurrent DVT occurs in approximately 20% of patients after 5 years, as reported by the Annals of Internal Medicine, with a higher risk for unprovoked DVT compared to provoked DVT 15, 16
• The risk of major bleeding with chronic warfarin therapy may reach 1-3% per year, according to the Genetics in Medicine guidelines 17